



## **Approval for Clinical Study on Antiplatelet Thrombolysin injection**

(Hong Kong, 20 February 2006) - Lee's Pharmaceutical Holdings Limited (GEM Stock: 8221: Website: [www.leespharm.com](http://www.leespharm.com)) announced today that the application for clinical study for the Group's in-house product~Declotana<sup>®</sup> (Antiplatelet Thrombolysin injection) has been approved by the SFDA of China.

Research and development work for this new drug project was initiated by the Group in 1995. In 1998, application for clinical study was formally submitted to SFDA. After the many years of internal hard works and supports from the SFDA, the Group has completed the required pre-clinical studies on the product's safety and efficacy profiles. In early February 2006, the Group received the approval notice from the SFDA to initiate clinical study for this new drug under Category 1 biopharmaceutical product with Approval Nos. 2005L04665, 2005L04666.

Declotana<sup>®</sup>~Antiplatelet Thrombolysin for injection, is a purified protein from snake venom of Bothropsatrox that possesses the anti-platelet 1b receptors activity and is an effective anti-thrombosis agent. Platelet 1b receptors are critical to platelet adhesion to damaged endothelin of blood vessel which leads to the activation of platelet and subsequent thrombus formation. Animal studies have shown that intravenous injection of Declotana<sup>®</sup> effectively abolishes the cyclic flow reduction in unstable angina model of dog with much less prolongation of bleeding time than platelet 2b3a receptors antagonist. Animal studies have also shown that Declotana<sup>®</sup> has a quite favorable safety profile. It is expected that Declotana<sup>®</sup> could have a role in preventing thrombosis and plaque progression at sites of pathological endothelial injury, contributing to the treatment of unstable angina as well as to reduction of restenosis in patients undergone PTCA and stenting.

As Asian countries begin to adopt more western lifestyles and foods, diseases such as cancer and cardiovascular diseases are becoming more prevalent in Asia. In China, cardiovascular diseases became the number two leading cause of death with over nine million deaths in every year. With its unique mechanism of action, Declotana<sup>®</sup> could offer new treatment option for the cardiovascular patients.

Dr. Benjamin Li, the Chief Executive Officer of the Group comments on this achievement by saying that "We are extremely excited about the successful development of this new drug. This is one of the most important milestones of the Group's development. This is the Group's first proprietary molecule with full intellectual rights that has been developed in-house. The approval is a compliment to the Group's research and development capability. It again ascertains our ability to move technology from benchside to bedside."

The Group will start the phase I study as soon as possible.

## About Lee's

Lee's Pharmaceutical Group, as a research-driven and market-oriented biopharmaceutical group, is actively pursuing for developing proprietary products and licensing technology/product from overseas prestigious biopharmaceutical institutions and companies.

### **Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*